Skip to content
General News, Medical Health Aged Care

Noisy knees not an early arthritis sign in young people, research shows

La Trobe University 2 mins read

Young adults who experience grinding or clicking sounds in their knees post-surgery may be alarmed, but new research from La Trobe University suggests these sounds may not signal early-onset osteoarthritis.  

Knee crepitus, the sound of cracking or grinding in the knee joint is very common across all age groups.   

The study, published in the Arthritis Care & Research journal, followed 112 young adults after anterior cruciate ligament (ACL) reconstruction, using Magnetic Resonance Imaging (MRI) scans and patient-reported outcomes to track osteoarthritis signs over five years. 

La Trobe graduate researcher and physiotherapist Jamon Couch said that while knee crepitus was linked to cartilage damage and worse symptoms one year after surgery, it did not predict joint damage over time. 

“We found that those with knee crepitus demonstrated more than two and a half times greater rates of full-thickness cartilage defects in the kneecap area, with more pain and poorer function early on,” Jamon said.  

“But over the next four years, those with crepitus did not experience worse pain and function compared to those without knee crepitus.” 

Research shows about 50 per cent of people with an ACL rupture will develop osteoarthritis symptoms and structural changes within a decade of injury, nearly 15 years earlier than the uninjured.  

The findings challenge the idea that crepitus should be used to diagnose or predict early osteoarthritis following traumatic knee injury in young adults.  

Dr Adam Culvenor, head of the Knee Injury Research Group at La Trobe’s Sport and Exercise Medicine Research Centre (LASEM) said the research would be reassuring for younger patients worried that noisy knees may be a red flag signalling their joint was deteriorating after surgery.  

“It also highlights the importance of staying active and engaged in rehabilitation to avoid or delay osteoarthritis,” Dr Culvenor said. 

The researchers say the study supports a more nuanced approach to diagnosing early-stage osteoarthritis and encourages health professionals to avoid overinterpreting crepitus in young, active patients. 

DOI: doi.org/10.1002/acr.25637 

Dr Adam Culvenor and Jamon Couch are available for interview. 


Media enquiries 

Debora McInnes d.mcinnes@latrobe.edu.au, 0487 448 734 

More from this category

  • General News, Music
  • 01/02/2026
  • 12:44
AFCM

Australian Festival of Chamber Music announces 2026 program – to be held in CAIRNS in 2026 in a new era for the famed event

Key Facts: Australian Festival of Chamber Music: 24 July – 1 August, 2026 MONDAY 2 FEBRUARY: tickets on sale to AFCM Friends MONDAY 2…

  • Contains:
  • Medical Health Aged Care, Mental Health
  • 31/01/2026
  • 06:37
MindEar

Help your brain filter out tinnitus and get your life back this Tinnitus Awareness Week

Experts available to talk about tinnitus, their family experience, and how new tools can make a difference for millions of people - in Sydney, Australia, and in Bristol and Newcastle (UK) A free trial of the latest evidence-based therapies is available for Tinnitus Awareness Week. The seven-day challenge incorporates the latest research from Newcastle University in the UK along with research from Auckland University, the Ear Institute at University College London and Leeds Trinity University. Many people living with tinnitus are still told that “nothing can be done” but clinicians following the latest research say that is bad advice which…

  • Contains:
  • Medical Health Aged Care
  • 31/01/2026
  • 00:10
Kyowa Kirin

Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis

Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential.Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease control in patients with moderate-to-severe atopic dermatitis (msAD).Regulatory submission is planned in the first half of 2026.TOKYO and PRINCETON, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the termination of the current rocatinlimab development and commercialization collaboration with Amgen. Kyowa Kirin will regain control of the global…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.